The malaria treatment market is expected to grow from US$ 1,638.27 million in 2021 to US$ 2,291.49 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2022 to 2028.
Malaria is a life-threatening infectious disease caused by the Plasmodium parasite. The market for malaria treatment is growing due to the high prevalence of malaria in low-income countries and global malaria elimination programs initiated by international and national organizations. Also, the increasing launch of advanced diagnostic tools and rising research activities to provide effective therapeutics are further driving the growth of the market.
Download sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00018229/
Zydus Healthcare Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Cipla Ltd, Viatris Inc, Lupin Ltd, AdvaCare Pharma USA LLC, and VLP Therapeutics LLC are among the leading companies operating in the malaria treatment market.
Government and private sector’s initiative for raising awareness about malaria act as a standalone factor responsible for the influential growth of the overall malaria treatment market. Malaria awareness campaigns help enhance knowledge regarding the disease and improve behaviors promoting health, along with promoting intersectoral collaboration and social support. The WHO is responsible for coordinating the Global Malaria Programme (GMP) as part of its global efforts to control and eradicate malaria. The program is led by the “Global Technical Strategy for Malaria 2016–2030,” which was adopted by the World Health Assembly in May 2015 and was further restructured in 2021. The WHO observes 25 April as World Malaria Day every year to highlight the collective energy and commitment of the malaria communities across the world in uniting for the common objective of freeing the world from malaria.
Governments in countries with a high prevalence of malaria are deploying various strategies to eradicate the disease by improving access to treatment and helping communities in malaria-endemic countries in delivering better healthcare. A few of these initiatives are mentioned below.
- Myanmar has a national malaria control plan that is approved by the Global Fund, and it expects to eliminate the disease caused by falciparum by 2030. The universal healthcare coverage in the country includes access to malaria diagnosis by microscopy or rapid diagnostic tests (RDTs) and the availability of artemisinin-based combination therapies (ACTs).
- Thailand has implemented the National Strategic Plan for Malaria Elimination that applies an integrated elimination strategy for the elimination of the disease by 2024.
- In January 2020, the Corporate Alliance on Malaria in Africa (CAMA) launched a strategic plan for 2021–2023. This plan aims to reach millions of people with malaria control interventions and scale up prevention activities in the region.
- Abbott collaborated with “Malaria No More” (a nonprofit organization to eradicate malaria) and the Government of Odisha, India, to provide technology, expertise, and funding to facilitate advanced efforts to end malaria in the state. In January 2019, Abbott announced its plans to supply one million RDTs to strengthen Odisha’s malaria diagnosis and surveillance system. The company also announced its plans to support “Malaria No More” with the financial aid of US$ 750,000 to support the malaria elimination strategy in the state.
Such initiatives by government and private companies to spread awareness about malaria and reinforce malaria eradication efforts are bolstering the malaria treatment market growth.
Inquiry Before Buying at: https://www.theinsightpartners.com/inquiry/TIPRE00018229/
Rapid Diagnostic Tests (RDTs) to Bolster Malaria Treatment Market Growth
RDTs for malaria can improve the quality of management of the disease. RDTs are proven to be highly affordable and effective for public health programs implemented in low-resource settings. RDTs are widely used in remote areas with limited access to microscopy services. As a result, there has been a rapid rise in the demand for RDTs for malaria. Several RDTs have been developed to test the presence of malaria parasites in blood samples. Identifying and successfully treating malaria in low transmission areas is critical to reduce transmission and achieve complete elimination of the disease. According to the WHO, more than 70% of malaria diagnostic testing is performed using RDTs in Africa. Many companies are engaged in developing a wide range of RDTs with high sensitivities. A few of these developments are mentioned below.
- In November 2020, researchers from Rice University developed a simple microneedle patch similar to a bandage to detect malaria. With this development, the researchers have stepped on the path of reducing the burden of disease in countries struggling with poor health infrastructure. The microneedles loaded on the patch collect interstitial fluid, which contains several biomarkers that help in detecting malaria.
- In June 2020, the Foundation for Innovative New Diagnostics (FIND) and Scanwell Health, a US-based company, partnered to develop a smartphone app that uses machine learning to read RDTs for malaria. This app would help healthcare professionals to interpret and record test results. With the expected compatibility with RDT kits and mobile devices, the app is likely to receive significant attention in low- and middle-income countries.
Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00018229/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi